Based on preclinical data suggesting potent anti-tumor activity of TYRP1-TCB (18) and the prevalence of TYRP1 expression in melanoma, we conducted a first-in-human (FIH) phase 1 dose escalation study (BP42169; NCT04551352) to investigate the safety, tolerability, maximum tolerated dose (MTD)/optimal biological dose, and pharmacokinetics (PK) of TYRP1-TCB in patients with metastatic melanoma. The gene discussed is TYRP1; the disease is neoplasm.